SCHEMBL4663315

SCHEMBL4663315

CCC=Cc1ccc(C(=O)O)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
TBXAS1 P24557 2/20 0.50
GRIK1 P39086 1/20 0.50
GRIK2 Q13002 1/20 0.50
FBP1 P09467 1/20 0.50
TDP1 Q9NUW8 2/20 0.48
GLA P06280 1/20 0.48
POLB P06746 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TP53 P04637 2/20 0.48
TSHR P16473 1/20 0.48
RARA P10276 2/20 0.48
RARB P10826 2/20 0.48
RARG P13631 2/20 0.48
XDH P47989 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
CYP3A4 P08684 1/20 0.45
MAPT P10636 1/20 0.45
ALOX15 P16050 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663311 1.00 ALDH1A1 (0.52) ALDH1A1TBXAS1GRIK1GRIK2FBP1
SCHEMBL6223194 0.85 ALDH1A1 (0.48) ALDH1A1TBXAS1GRIK1GRIK2FBP1
SCHEMBL6294879 0.85 ALDH1A1 (0.48) ALDH1A1TBXAS1GRIK1GRIK2FBP1
SCHEMBL26455401 0.85 ALDH1A1 (0.48) ALDH1A1TBXAS1GRIK1GRIK2FBP1
SCHEMBL4101060 0.84 KMT2A (0.47) L3MBTL1KMT2ASMN1; SMN2MAPTMAPK1
SCHEMBL4101063 0.84 KMT2A (0.47) L3MBTL1KMT2ASMN1; SMN2MAPTMAPK1
SCHEMBL28976980 0.82 MAPT (0.39) ALDH1A1TBXAS1GRIK1GRIK2TDP1
SCHEMBL2787514 0.82 RARB (0.47) ALDH1A1TBXAS1GRIK1GRIK2FBP1
SCHEMBL11112597 0.82 ALDH1A1 (0.54) ALDH1A1TBXAS1GRIK1GRIK2FBP1
SCHEMBL11112595 0.82 ALDH1A1 (0.54) ALDH1A1TBXAS1GRIK1GRIK2FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115850080-B Fluorescent liquid crystal small molecule with temperature-controlled optical texture and photoluminescence dual anti-counterfeiting mechanism and preparation method thereof 徐州工程学院 2023-10-03 CN claimed
CN-115850080-A Fluorescent liquid crystal micromolecule with temperature-controlled optical texture and photoluminescence double anti-counterfeiting mechanisms and preparation method thereof 徐州工程学院 2023-03-28 CN claimed
CN-115850080-B Fluorescent liquid crystal small molecule with temperature-controlled optical texture and photoluminescence dual anti-counterfeiting mechanism and preparation method thereof 徐州工程学院 2023-10-03 CN disclosed
CN-115850080-A Fluorescent liquid crystal micromolecule with temperature-controlled optical texture and photoluminescence double anti-counterfeiting mechanisms and preparation method thereof 徐州工程学院 2023-03-28 CN disclosed
CN-109071484-A Molecule with desinsection effectiveness, and intermediate relevant to these molecules, composition and method 美国陶氏益农公司 2018-12-21 CN disclosed
US-20130128359-A1 OPTICAL FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY APPARATUS FUJIFILM CORPORATION (JP) 2013-05-23 US disclosed
EP-1364957-B1 GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL (JP) 2008-12-31 EP disclosed
US-20080113121-A1 Cyclic polyolefin film, and polarizing plate and liquid crystal display device using the same FUJIFILM CORPORATION (JP) 2008-05-15 US disclosed
US-7189702-B2 Glucopyranosyloxypyrazole derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2007-03-13 US disclosed
US-7087579-B2 Glucopyranosyloxypyrazole derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2006-08-08 US disclosed
US-20060142209-A1 Glucopyranosyloxypyrazole derivatives and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. 2006-06-29 US disclosed
US-20040132669-A1 Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs KISSEI PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
EP-1364957-A1 GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2003-11-26 EP disclosed
EP-0570932-B1 Styrenic block copolymer and process for producing same IDEMITSU KOSAN CO (JP) 1997-07-23 EP disclosed
US-5418290-A Compatability with other resins, adhesion IDEMITSU KOSAN CO., LTD. (JP) 1995-05-23 US disclosed
US-5391626-A Syndiotactic, high performance, compatibility and adhesiveness; molding materials IDEMITSU KOSAN CO., LTD. (JP) 1995-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132669-A1 Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs SLC5A2, SLC5A1, SLC2A1 ALDH1A1 596/4885TBXAS1 3139/4885GRIK1 2867/4885
US-20060142209-A1 Glucopyranosyloxypyrazole derivatives and medicinal use thereof SLC5A2, SLC5A1, UGGT1 ALDH1A1 570/4885TBXAS1 2654/4885GRIK1 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.